mitoxantrone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastics; anthraquinone derivatives	1821	65271-80-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mitoxantrone mitoxantrone hydrochloride dihydroxyanthraquinone mitoxanthrone mitozantrone nimitoxantron mitoxantrone dihydrochloride mitoxantrone HCl	An anthracenedione-derived antineoplastic agent. Molecular weight: 444.49 Formula: C22H28N4O6 CLOGP: 2.24 LIPINSKI: 1 HAC: 10 HDO: 8 TPSA: 163.18 ALOGS: -2.78 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mitoxantrone
mitoxantrone hydrochloride
dihydroxyanthraquinone
mitoxanthrone
mitozantrone
nimitoxantron
mitoxantrone dihydrochloride
mitoxantrone HCl

An anthracenedione-derived antineoplastic agent.

Molecular weight: 444.49
Formula: C22H28N4O6
CLOGP: 2.24
LIPINSKI: 1
HAC: 10
HDO: 8
TPSA: 163.18
ALOGS: -2.78
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.59 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	7 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.78 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	7.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.25 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	53 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 23, 1987	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	361.51	25.39	194	6203	118255	63364370
Acute myeloid leukaemia	252.34	25.39	86	6311	17061	63465564
Myelodysplastic syndrome	174.30	25.39	65	6332	16689	63465936
Pancytopenia	145.37	25.39	101	6296	96832	63385793
Sepsis	132.21	25.39	115	6282	153008	63329617
Second primary malignancy	125.22	25.39	42	6355	7911	63474714
Acute promyelocytic leukaemia	103.78	25.39	23	6374	904	63481721
Thrombocytopenia	98.35	25.39	97	6300	151060	63331565
Neutropenia	97.00	25.39	103	6294	174902	63307723
Leukaemia recurrent	90.26	25.39	22	6375	1316	63481309
Bone marrow failure	72.60	25.39	42	6355	29248	63453377
Acute myeloid leukaemia recurrent	71.54	25.39	19	6378	1604	63481021
Haemophagocytic lymphohistiocytosis	71.12	25.39	30	6367	10597	63472028
Progressive multifocal leukoencephalopathy	68.53	25.39	31	6366	12940	63469685
Bronchopulmonary aspergillosis	63.25	25.39	26	6371	8609	63474016
Febrile bone marrow aplasia	56.88	25.39	23	6374	7302	63475323
Chronic hepatitis	56.72	25.39	14	6383	882	63481743
Haematotoxicity	54.63	25.39	24	6373	9352	63473273
Strongyloidiasis	52.12	25.39	14	6383	1234	63481391
Congestive cardiomyopathy	50.04	25.39	20	6377	6162	63476463
Hypogammaglobulinaemia	47.21	25.39	20	6377	7135	63475490
Lower respiratory tract infection fungal	46.84	25.39	10	6387	329	63482296
Cardiac failure	44.96	25.39	50	6347	89092	63393533
Mucormycosis	44.53	25.39	15	6382	2856	63479769
Product use in unapproved indication	44.53	25.39	71	6326	179009	63303616
Chloroma	44.19	25.39	9	6388	234	63482391
Streptococcal bacteraemia	42.90	25.39	13	6384	1764	63480861
Graft versus host disease	41.64	25.39	18	6379	6745	63475880
Venoocclusive liver disease	40.37	25.39	16	6381	4819	63477806
Cardiomyopathy	40.36	25.39	24	6373	17560	63465065
Bone marrow infiltration	39.85	25.39	10	6387	674	63481951
Acute lymphocytic leukaemia recurrent	39.77	25.39	13	6384	2256	63480369
Abdominal wall wound	39.40	25.39	7	6390	85	63482540
Haemorrhagic adrenal infarction	38.31	25.39	6	6391	31	63482594
Respiratory failure	37.98	25.39	49	6348	101809	63380816
Multiple organ dysfunction syndrome	37.88	25.39	37	6360	56715	63425910
Myeloblast percentage decreased	36.87	25.39	6	6391	41	63482584
Refractory cytopenia with multilineage dysplasia	36.08	25.39	7	6390	141	63482484
Arthralgia	35.87	25.39	7	6390	569703	62912922
Aspergillus infection	35.47	25.39	17	6380	8076	63474549
Pain	34.26	25.39	16	6381	740612	62742013
Hepatitis E	32.46	25.39	10	6387	1434	63481191
Neoplasm progression	30.59	25.39	27	6370	36401	63446224
Stem cell transplant	30.17	25.39	10	6387	1812	63480813
Leukopenia	30.09	25.39	38	6359	77252	63405373
Bacterial sepsis	29.26	25.39	12	6385	3946	63478679
Fatigue	29.25	25.39	28	6369	888000	62594625
Stenotrophomonas infection	29.12	25.39	10	6387	2017	63480608
Cardiotoxicity	28.92	25.39	15	6382	8423	63474202
Myelofibrosis	28.70	25.39	9	6388	1368	63481257
Clostridium bacteraemia	28.02	25.39	6	6391	200	63482425
Graft versus host disease in gastrointestinal tract	28.02	25.39	11	6386	3230	63479395
Chronic myeloid leukaemia	27.81	25.39	10	6387	2308	63480317
Malignant neoplasm progression	26.76	25.39	37	6360	82084	63400541
Differentiation syndrome	26.33	25.39	8	6389	1095	63481530
Pyrexia	26.17	25.39	105	6292	470373	63012252
Guillain-Barre syndrome	26.07	25.39	11	6386	3882	63478743
Colitis	25.79	25.39	28	6369	48500	63434125
Streptococcal sepsis	25.64	25.39	9	6388	1937	63480688

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	387.97	20.96	280	7135	136569	34812947
Myelodysplastic syndrome	171.67	20.96	83	7332	19125	34930391
Acute myeloid leukaemia	145.51	20.96	73	7342	18197	34931319
Neutropenia	119.40	20.96	156	7259	156622	34792894
Septic shock	113.46	20.96	105	7310	71729	34877787
Bronchopulmonary aspergillosis	83.88	20.96	47	7368	14612	34934904
Mucormycosis	82.67	20.96	35	7380	5907	34943609
Bone marrow failure	82.54	20.96	60	7355	29193	34920323
Second primary malignancy	73.18	20.96	35	7380	7851	34941665
Fungal infection	69.85	20.96	43	7372	15892	34933624
Bacteraemia	63.84	20.96	44	7371	19673	34929843
Thrombocytopenia	51.92	20.96	107	7308	156140	34793376
Minimal residual disease	51.37	20.96	13	7402	424	34949092
Ameloblastoma	51.19	20.96	10	7405	94	34949422
Aspiration bone marrow abnormal	48.23	20.96	10	7405	130	34949386
Pneumonia fungal	46.78	20.96	25	7390	7075	34942441
Leukaemia recurrent	45.86	20.96	16	7399	1599	34947917
Multiple organ dysfunction syndrome	45.80	20.96	68	7347	76498	34873018
Hypertensive hydrocephalus	42.11	20.96	8	7407	64	34949452
Disease progression	39.42	20.96	77	7338	108000	34841516
Acute lymphocytic leukaemia recurrent	39.27	20.96	17	7398	3027	34946489
Aspergillus infection	38.84	20.96	27	7388	12227	34937289
Venoocclusive liver disease	38.77	20.96	23	7392	7943	34941573
Neoplasm progression	38.52	20.96	35	7380	23265	34926251
Cytogenetic abnormality	37.96	20.96	12	7403	883	34948633
Haematopoietic neoplasm	37.67	20.96	7	7408	49	34949467
Myelosuppression	35.95	20.96	31	7384	19234	34930282
Pancytopenia	34.93	20.96	68	7347	95089	34854427
Cardiotoxicity	34.73	20.96	19	7396	5629	34943887
Neoplasm recurrence	33.80	20.96	14	7401	2235	34947281
Mucosal inflammation	33.29	20.96	41	7374	38581	34910935
Neutropenic colitis	32.38	20.96	15	7400	3129	34946387
Cystitis haemorrhagic	31.90	20.96	18	7397	5661	34943855
Abscess fungal	31.88	20.96	8	7407	252	34949264
Sepsis	30.64	20.96	91	7324	166470	34783046
Febrile bone marrow aplasia	30.59	20.96	20	7395	8189	34941327
Gallbladder adenocarcinoma	30.37	20.96	5	7410	15	34949501
Klebsiella infection	29.89	20.96	20	7395	8511	34941005
Clostridium bacteraemia	29.26	20.96	7	7408	180	34949336
Refractory anaemia with an excess of blasts	28.13	20.96	8	7407	409	34949107
Respiratory tract infection fungal	27.76	20.96	9	7406	718	34948798
Drug ineffective	26.99	20.96	177	7238	456574	34492942
Genotoxicity	26.78	20.96	5	7410	36	34949480
Enamel anomaly	26.56	20.96	6	7409	119	34949397
Product use in unapproved indication	26.32	20.96	69	7346	117430	34832086
Osteonecrosis	25.85	20.96	23	7392	14867	34934649
Progressive multifocal leukoencephalopathy	25.20	20.96	19	7396	9745	34939771
Lymphoma	25.12	20.96	21	7394	12486	34937030
Klebsiella sepsis	25.05	20.96	11	7404	2026	34947490
Encephalopathy	24.97	20.96	34	7381	35285	34914231
Septal panniculitis	24.56	20.96	5	7410	59	34949457
Hyperammonaemic encephalopathy	23.66	20.96	11	7404	2313	34947203
Colitis	23.22	20.96	34	7381	37716	34911800
Large granular lymphocytosis	23.08	20.96	6	7409	218	34949298
Diffuse large B-cell lymphoma recurrent	23.06	20.96	12	7403	3216	34946300
Fungaemia	22.61	20.96	11	7404	2557	34946959
Gene mutation	21.96	20.96	9	7406	1399	34948117
Cerebral aspergillosis	21.81	20.96	9	7406	1423	34948093
Differentiation syndrome	21.77	20.96	9	7406	1429	34948087
Cholangitis infective	21.71	20.96	6	7409	276	34949240
Fall	21.66	20.96	8	7407	202877	34746639
Drug resistance	21.49	20.96	27	7388	25900	34923616
Tooth hypoplasia	21.19	20.96	5	7410	121	34949395
Blood culture positive	21.18	20.96	13	7402	4770	34944746

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	616.32	20.71	399	11562	230600	79501827
Acute myeloid leukaemia	377.15	20.71	150	11811	30735	79701692
Myelodysplastic syndrome	338.32	20.71	138	11823	30163	79702264
Second primary malignancy	193.69	20.71	75	11886	14275	79718152
Neutropenia	184.47	20.71	221	11740	287489	79444938
Bone marrow failure	154.64	20.71	96	11865	51011	79681416
Sepsis	130.12	20.71	180	11781	269248	79463179
Leukaemia recurrent	125.04	20.71	36	11925	2738	79729689
Thrombocytopenia	124.78	20.71	175	11786	265084	79467343
Septic shock	121.87	20.71	119	11842	122682	79609745
Pancytopenia	117.09	20.71	134	11827	165611	79566816
Bronchopulmonary aspergillosis	108.11	20.71	57	11904	22237	79710190
Mucormycosis	95.88	20.71	39	11922	8430	79723997
Acute promyelocytic leukaemia	93.16	20.71	25	11936	1466	79730961
Venoocclusive liver disease	83.53	20.71	39	11922	11732	79720695
Bacteraemia	80.35	20.71	54	11907	32770	79699657
Multiple organ dysfunction syndrome	76.17	20.71	92	11869	120154	79612273
Progressive multifocal leukoencephalopathy	76.03	20.71	44	11917	20556	79711871
Acute myeloid leukaemia recurrent	72.97	20.71	25	11936	3358	79729069
Acute lymphocytic leukaemia recurrent	72.03	20.71	27	11934	4697	79727730
Product use in unapproved indication	68.10	20.71	129	11832	250230	79482197
Fungal infection	66.55	20.71	53	11908	41695	79690732
Aspergillus infection	60.47	20.71	37	11924	19124	79713303
Febrile bone marrow aplasia	59.48	20.71	32	11929	12988	79719439
Haemophagocytic lymphohistiocytosis	58.47	20.71	38	11923	21799	79710628
Clostridium bacteraemia	57.05	20.71	13	11948	385	79732042
Cytogenetic abnormality	57.01	20.71	16	11945	1109	79731318
Ameloblastoma	54.65	20.71	10	11951	94	79732333
Neoplasm recurrence	53.22	20.71	21	11940	4193	79728234
Disease progression	51.33	20.71	96	11865	184266	79548161
Lower respiratory tract infection fungal	51.31	20.71	14	11947	874	79731553
Refractory anaemia with an excess of blasts	51.03	20.71	14	11947	892	79731535
Neoplasm progression	49.17	20.71	49	11912	51633	79680794
Chronic hepatitis	48.76	20.71	15	11946	1432	79730995
Neutropenic colitis	47.07	20.71	21	11940	5686	79726741
Haematotoxicity	46.51	20.71	29	11932	15490	79716937
Respiratory failure	46.42	20.71	91	11870	180820	79551607
Drug resistance	45.76	20.71	43	11918	42170	79690257
Myelosuppression	45.52	20.71	42	11919	40254	79692173
Cardiotoxicity	44.78	20.71	26	11935	12213	79720214
Cardiomyopathy	44.72	20.71	36	11925	28738	79703689
Differentiation syndrome	44.29	20.71	16	11945	2508	79729919
Pneumonia fungal	44.19	20.71	25	11936	11185	79721242
Klebsiella sepsis	43.87	20.71	17	11944	3235	79729192
Fatigue	41.70	20.71	47	11914	929680	78802747
Fungaemia	41.44	20.71	18	11943	4573	79727854
Hypogammaglobulinaemia	40.84	20.71	25	11936	12926	79719501
Graft versus host disease	39.86	20.71	26	11935	15000	79717427
Arthralgia	39.86	20.71	18	11943	571785	79160642
Enterococcal infection	38.88	20.71	26	11935	15634	79716793
Stem cell transplant	38.33	20.71	16	11945	3688	79728739
Pain	38.06	20.71	30	11931	703772	79028655
Malignant neoplasm progression	38.06	20.71	71	11890	135919	79596508
Stenotrophomonas infection	38.05	20.71	16	11945	3757	79728670
Aplastic anaemia	38.02	20.71	27	11934	17878	79714549
Drug ineffective	37.97	20.71	284	11677	1080629	78651798
Staphylococcal infection	37.52	20.71	45	11916	58250	79674177
Haematopoietic neoplasm	36.47	20.71	7	11954	87	79732340
Diffuse large B-cell lymphoma recurrent	36.37	20.71	16	11945	4191	79728236
Candida infection	35.92	20.71	36	11925	38178	79694249
Abdominal wall wound	35.83	20.71	7	11954	96	79732331
Colitis	35.28	20.71	49	11912	73258	79659169
Cardiac failure	35.09	20.71	74	11887	154768	79577659
Cystitis haemorrhagic	34.93	20.71	20	11941	9152	79723275
Myeloblast percentage decreased	34.49	20.71	6	11955	41	79732386
Hyperammonaemic encephalopathy	34.41	20.71	16	11945	4766	79727661
Respiratory tract infection fungal	34.31	20.71	11	11950	1202	79731225
Refractory cytopenia with multilineage dysplasia	34.30	20.71	8	11953	263	79732164
Disseminated intravascular coagulation	34.12	20.71	34	11927	35808	79696619
Klebsiella infection	34.07	20.71	24	11937	15696	79716731
Hypertensive hydrocephalus	33.54	20.71	5	11956	10	79732417
Stomatococcal infection	33.36	20.71	8	11953	297	79732130
Pyrexia	32.61	20.71	193	11768	678516	79053911
Chronic lymphocytic leukaemia recurrent	31.86	20.71	9	11952	639	79731788
Pruritus	31.51	20.71	10	11951	394638	79337789
Fall	31.47	20.71	17	11944	487612	79244815
Drug hypersensitivity	31.24	20.71	4	11957	298912	79433515
Hepatic failure	31.09	20.71	42	11919	61170	79671257
Strongyloidiasis	31.05	20.71	14	11947	3884	79728543
Acute lymphocytic leukaemia	30.78	20.71	15	11946	4954	79727473
Nausea	30.65	20.71	61	11900	957135	78775292
Bone marrow infiltration	30.60	20.71	9	11952	737	79731690
Chloroma	30.32	20.71	9	11952	761	79731666
Mucosal inflammation	29.82	20.71	46	11915	75534	79656893
Leukopenia	29.12	20.71	58	11903	116455	79615972
Osteonecrosis	28.68	20.71	29	11932	31066	79701361
Chronic myeloid leukaemia	28.68	20.71	13	11948	3651	79728776
Hepatitis B	28.64	20.71	17	11944	8315	79724112
Pulmonary haemorrhage	28.53	20.71	21	11940	14696	79717731
Acute febrile neutrophilic dermatosis	28.00	20.71	13	11948	3859	79728568
Encephalopathy	27.97	20.71	42	11919	67355	79665072
Dizziness	27.72	20.71	23	11938	526418	79206009
Nasopharyngitis	27.51	20.71	3	11958	253878	79478549
Acute myeloid leukaemia refractory	27.27	20.71	6	11955	151	79732276
Abscess fungal	27.11	20.71	7	11954	353	79732074
Escherichia bacteraemia	26.85	20.71	15	11946	6547	79725880
Aspiration bone marrow abnormal	26.69	20.71	6	11955	167	79732260
Pain in extremity	26.12	20.71	11	11950	364527	79367900
Off label use	26.11	20.71	228	11733	906987	78825440
Pseudomonas infection	25.99	20.71	23	11938	20880	79711547
Blood culture positive	25.88	20.71	16	11945	8413	79724014
Streptococcal bacteraemia	25.74	20.71	12	11949	3594	79728833
Lymphopenia	25.49	20.71	27	11934	30530	79701897
Minimal residual disease	24.73	20.71	7	11954	500	79731927
Hepatitis E	24.67	20.71	11	11950	2975	79729452
Graft versus host disease in gastrointestinal tract	24.58	20.71	14	11947	6342	79726085
Chromosome analysis abnormal	24.42	20.71	6	11955	247	79732180
Weight increased	24.04	20.71	6	11955	277380	79455047
Acute graft versus host disease	23.14	20.71	16	11945	10151	79722276
Portal hypertension	23.12	20.71	14	11947	7094	79725333
Acute myelomonocytic leukaemia	22.95	20.71	6	11955	318	79732109
Cytomegalovirus infection	22.78	20.71	30	11931	42614	79689813
Septal panniculitis	22.46	20.71	5	11956	133	79732294
Pseudomonal sepsis	22.28	20.71	13	11948	6161	79726266
Leukaemic infiltration	22.11	20.71	5	11956	143	79732284
Large granular lymphocytosis	21.95	20.71	6	11955	377	79732050
Diarrhoea	21.90	20.71	64	11897	880425	78852002
Streptococcal sepsis	21.77	20.71	10	11951	2897	79729530
Chromosomal deletion	21.48	20.71	5	11956	163	79732264
Bacterial sepsis	21.29	20.71	14	11947	8184	79724243
Chronic graft versus host disease	21.15	20.71	13	11948	6768	79725659
Pneumonia	21.11	20.71	170	11791	660076	79072351
Chronic myelomonocytic leukaemia	21.04	20.71	7	11954	859	79731568
Cerebral fungal infection	21.03	20.71	6	11955	441	79731986
Metastasis	20.97	20.71	13	11948	6867	79725560
Primary hypogonadism	20.95	20.71	5	11956	182	79732245
Retinal infiltrates	20.89	20.71	4	11957	49	79732378
Parametritis	20.87	20.71	3	11958	4	79732423

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01DB07	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances
FDA MoA	N0000000176	Topoisomerase Inhibitors
MeSH PA	D000700	Analgesics
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D059005	Topoisomerase II Inhibitors
MeSH PA	D059003	Topoisomerase Inhibitors
FDA EPC	N0000175609	Topoisomerase Inhibitor
CHEBI has role	CHEBI:23240	chromophores
CHEBI has role	CHEBI:37958	dyes
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:35610	antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute myeloid leukemia, disease	indication	91861009
Relapsing remitting multiple sclerosis	indication	426373005	DOID:2378
Metastatic Prostate Carcinoma	indication
Follicular non-Hodgkin's lymphoma	off-label use	308121000
Metastatic Breast Carcinoma	off-label use
Progressive Diffuse Large B-Cell Lymphoma	off-label use
Mycosis	contraindication	3218000	DOID:1564
Viral disease	contraindication	34014006	DOID:934
Chronic heart failure	contraindication	48447003
Hepatic failure	contraindication	59927004
Acute infectious disease	contraindication	63171007
Leukopenia	contraindication	84828003	DOID:615
Left heart failure	contraindication	85232009
Bacterial infectious disease	contraindication	87628006
Radiation oncology AND/OR radiotherapy	contraindication	108290001
Acute disease of cardiovascular system	contraindication	128487001
Seizure disorder	contraindication	128613002
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.37	acidic
pKa2	10.7	acidic
pKa3	9.13	Basic
pKa4	8.52	Basic
pKa5	4.01	Basic
pKa6	1.49	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
DNA topoisomerase 2-alpha	Enzyme	P11388	TOP2A_HUMAN	INHIBITOR	IC90	5.96	WOMBAT-PK	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.84	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.31	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.73	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.74	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.11	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.05	DRUG MATRIX
Canalicular multispecific organic anion transporter 1	Transporter	Q92887	MRP2_HUMAN				WOMBAT-PK
Multidrug resistance-associated protein 1	Transporter	P33527	MRP1_HUMAN		IC50	6.29	WOMBAT-PK
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		Kact	5.16	WOMBAT-PK
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.27	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.90	DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	5.69	DRUG MATRIX
Serine/threonine-protein kinase pim-1	Kinase	P11309	PIM1_HUMAN		IC50	7.29	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.36	CHEMBL
DNA-(apurinic or apyrimidinic site) lyase	Enzyme	P27695	APEX1_HUMAN		IC50	5.70	CHEMBL
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN		IC50	6	CHEMBL
Proto-oncogene tyrosine-protein kinase ROS	Kinase	P08922	ROS1_HUMAN		IC50	5.52	CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.13	CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	6.72	CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN		IC50	6.28	CHEMBL
Solute carrier family 22 member 3	Transporter	O75751	S22A3_HUMAN		IC50	4.22	CHEMBL
DNA-3-methyladenine glycosylase	Enzyme	P29372	3MG_HUMAN		IC50	5.60	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.53	DRUG MATRIX
TAR DNA-binding protein 43	Unclassified	Q13148	TADBP_HUMAN		IC50	5	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	5.75	DRUG MATRIX
Integrase	Enzyme		Q7ZJM1_9HIV1		IC50	5.42	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Kinase		DYR1A_RAT		AC50	5.02	CHEMBL

External reference:

ID	Source
4019842	VUID
N0000147929	NUI
D02166	KEGG_DRUG
70476-82-3	SECONDARY_CAS_RN
4019527	VANDF
4019842	VANDF
C0026259	UMLSCUI
CHEBI:50729	CHEBI
MIX	PDB_CHEM_ID
CHEMBL58	ChEMBL_ID
CHEMBL1417019	ChEMBL_ID
CHEMBL1200827	ChEMBL_ID
D008942	MESH_DESCRIPTOR_UI
DB01204	DRUGBANK_ID
7242	IUPHAR_LIGAND_ID
4922	INN_ID
BZ114NVM5P	UNII
4212	PUBCHEM_CID
203129	RXNORM
5124	MMSL
81184	MMSL
d00306	MMSL
002676	NDDF
004828	NDDF
108791001	SNOMEDCT_US
386913001	SNOMEDCT_US
412249002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4680	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4680	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4685	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4685	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4686	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
mitoXANTRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4686	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	24 sections
Mitoxantrone	HUMAN PRESCRIPTION DRUG LABEL	1	61703-343	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	28 sections
Mitoxantrone	HUMAN PRESCRIPTION DRUG LABEL	1	61703-343	INJECTION, SOLUTION, CONCENTRATE	2 mg	INTRAVENOUS	ANDA	28 sections
Mitoxantrone	HUMAN PRESCRIPTION DRUG LABEL	1	63323-132	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	15 sections